FHS
0.002
100%
LIB
0.002
-33.3%
AHNDA
0.09
76.5%
PER
0.003
-25%
AMD
0.005
66.7%
MHM
0.12
-17.2%
BLU
0.004
33.3%
SHO
0.039
-17%
JCS
0.04
33.3%
CCX
0.054
-16.9%
TAT
0.026
30%
BTN
0.015
-16.7%
PET
0.006
20%
GNM
0.035
-16.7%
AHF
0.019
18.8%
IPD
0.005
-16.7%
CYG
0.395
17.9%
XRA
0.18
-16.3%
BSR
0.34
17.2%
EM3
0.12
-15.5%
RFT
0.007
16.7%
CPO
0.011
-15.4%
CHL
0.19
15.2%
REE
0.011
-15.4%
EMC
0.115
15%
AXQ
4.61
-15.1%
BUX
0.047
14.6%
AON
0.047
-14.5%
LCL
0.008
14.3%
4DX
3.245
-14.4%
ALB
0.051
13.3%
BNL
0.006
-14.3%
CDE
0.009
12.5%
EXT
0.006
-14.3%
D3E
0.345
11.3%
FEL
0.006
-14.3%
88E
0.02
11.1%
PL9
0.006
-14.3%
SER
0.15
11.1%
PNT
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PYC Therapeutics (ASX:PYC): Reports vision improvement in multiple RP11 patients

PYC Therapeutics (ASX:PYC) has developed the only clinical-stage investigational drug candidate designed specifically for patients with the blinding eye disease Retinitis Pigmentosa type 11 (RP11).

👁️ PYC recently reported an improvement in vision in 2 patients with RP11
📣 PYC will announce further results from the ongoing multiple dose studies of VP-001 in Q4 2024
🧪 PYC is now preparing for a registrational trial that will be designed to support a new drug application and commercial launch of this drug candidate 4

ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20240812/pdf/066j27mrjnft47.pdf